Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 3

2(22.2%)

Phase 2

1(11.1%)

9Total

Phase 1(6)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00710697Phase 1Unknown

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

Role: lead

NCT00465725Phase 1Completed

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Role: lead

NCT00465491Phase 3Unknown

Study of Picoplatin Efficacy After Relapse

Role: lead

NCT00045136Phase 1Completed

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Role: lead

NCT00083564Phase 3Terminated

Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma

Role: lead

NCT00039754Phase 1Terminated

A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma

Role: lead

NCT00116610Phase 2Completed

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Role: lead

NCT00478946Phase 1Unknown

A Study of Picoplatin in Colorectal Cancer

Role: lead

NCT00448734Phase 1Unknown

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

Role: lead

All 9 trials loaded